B.Riley FBR analyst Kara Anderson maintained a Hold rating on Heska Corp (NASDAQ: HSKA) today and set a price target of $93. The company’s shares opened today at $100.29.
Anderson commented:
“PT) will report 2Q18 results before market open on and hold a conference call to discuss earnings at 11:00 a.m. ET (dial in: ID# 9053418). Heska already reset expectations and lowered the bar for 2Q18 at its Investor Day in May. Given the timeliness of the increased visibility (management does not normally provide quarterly guidance), we do not expect the print to materially deviate from expectations. We forecast 2Q revenue of $30.3 million, operating income of $1.7 million, and EPS of $0.16 relative to consensus $30.1 million, $1.8 million, and $0.16, respectively. The company provided quarterly cadence for FY18 that called for 2Q revenue of $30.0 million, a gross margin near 43%, and operating income of $1.7 million.”
According to TipRanks.com, Anderson is a 4-star analyst with an average return of 12.6% and a 53.3% success rate. Anderson covers the Services sector, focusing on stocks such as Weight Watchers International, Spark Networks Plc, and Nutrisystem Inc.
Heska Corp has an analyst consensus of Strong Buy, with a price target consensus of $110.25.
See today’s analyst top recommended stocks >>
The company has a one-year high of $111.93 and a one-year low of $56.59. Currently, Heska Corp has an average volume of 62.45K.
Based on the recent corporate insider activity of 30 insiders, corporate insider sentiment is negative on the stock. Most recently, in May 2018, Bonnie Trowbridge, a Director at HSKA sold 5,000 shares for a total of $505,029.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Heska Corp. engages in the provision of veterinary and animal health diagnostic, and specialty products. It operates through the Core Companion Animal Health; and Other Vaccines, and Pharmaceuticals and Products segments.
